These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38524646)

  • 1. Response to capmatinib in a patient with neuroendocrine carcinoma of the gallbladder origin harboring
    Yamamura S; Kanai M; Takeuchi Y; Okita N; Kondo T; Yoshioka M; Matsubara J; Matsumoto S; Muto M
    Int Cancer Conf J; 2024 Apr; 13(2):83-87. PubMed ID: 38524646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Focal neuroendocrine carcinoma mixed with adenocarcinoma of the gallbladder with aggressive lymph node metastasis in a patient who did not meet the mixed neuroendocrine-non-neuroendocrine neoplasm criteria.
    Kadota Y; Funakoshi S; Hirose S; Shiomi E; Odaira M; Yagishita H; Kobayashi Y; Toriumi F; Tamai S; Endo T; Harada H
    Clin J Gastroenterol; 2022 Feb; 15(1):185-191. PubMed ID: 34767241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
    Wu YL; Smit EF; Bauer TM
    Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capmatinib in
    Wolf J; Seto T; Han JY; Reguart N; Garon EB; Groen HJM; Tan DSW; Hida T; de Jonge M; Orlov SV; Smit EF; Souquet PJ; Vansteenkiste J; Hochmair M; Felip E; Nishio M; Thomas M; Ohashi K; Toyozawa R; Overbeck TR; de Marinis F; Kim TM; Laack E; Robeva A; Le Mouhaer S; Waldron-Lynch M; Sankaran B; Balbin OA; Cui X; Giovannini M; Akimov M; Heist RS;
    N Engl J Med; 2020 Sep; 383(10):944-957. PubMed ID: 32877583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor.
    Dagogo-Jack I; Moonsamy P; Gainor JF; Lennerz JK; Piotrowska Z; Lin JJ; Lennes IT; Sequist LV; Shaw AT; Goodwin K; Stevens SE; Do A; Digumarthy SR; Price K; Muzikansky A; Hata AN; Heist RS
    J Thorac Oncol; 2021 May; 16(5):850-859. PubMed ID: 33545388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.
    Choi W; Park SY; Lee Y; Lim KY; Park M; Lee GK; Han JY
    Cancer Res Treat; 2021 Oct; 53(4):1024-1032. PubMed ID: 33540494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review.
    Hsu R; Benjamin DJ; Nagasaka M
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYC amplification-conferred primary resistance to capmatinib in a
    Choi W; Jeong KC; Park SY; Kim S; Kang EH; Hwang M; Han JY
    Transl Lung Cancer Res; 2022 Sep; 11(9):1967-1972. PubMed ID: 36248327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed neuroendocrine non-neuroendocrine neoplasm of the gallbladder complicated by a pancreaticobiliary maljunction of a non-dilated biliary duct: A case report.
    Wagatsuma K; Akita K; Motoya M; Kimura Y; Sugita S; Hirano T; Kawakami Y; Numata Y; Ishigami K; Masaki Y; Murota A; Shitani M; Akutsu N; Sasaki S; Nakase H
    Medicine (Baltimore); 2021 Oct; 100(39):e27336. PubMed ID: 34596138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion Diagnostics.
    Guo MZ; Marrone KA; Spira A; Waterhouse DM; Scott SC
    Onco Targets Ther; 2021; 14():5321-5331. PubMed ID: 34853516
    [No Abstract]   [Full Text] [Related]  

  • 11. Interstitial lung disease associated with capmatinib therapy in a patient with non-small cell lung cancer harboring a skipping mutation of MET exon 14.
    Kanemura H; Takeda M; Shimizu S; Nakagawa K
    Thorac Cancer; 2021 Feb; 12(4):549-552. PubMed ID: 33347701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a
    Cai B; Zhou ZY; Xue W; Hazra NC; Singh M; Mishra D; Brixner D; Oderda G; Biskupiak J
    J Med Econ; 2021; 24(1):131-139. PubMed ID: 33397178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capmatinib in MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma with Extensive Central Nervous System Metastasis.
    Kim TW; Lee KM; Lee SH
    Onco Targets Ther; 2022; 15():941-946. PubMed ID: 36072511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.
    Kim S; Kim TM; Kim DW; Kim S; Kim M; Ahn YO; Keam B; Heo DS
    Cancer Res Treat; 2019 Jul; 51(3):951-962. PubMed ID: 30309221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives.
    Fraser M; Seetharamu N; Diamond M; Lee CS
    Cancer Manag Res; 2023; 15():1233-1243. PubMed ID: 37941971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capmatinib for the treatment of non-small cell lung cancer.
    Vansteenkiste JF; Van De Kerkhove C; Wauters E; Van Mol P
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):659-671. PubMed ID: 31368815
    [No Abstract]   [Full Text] [Related]  

  • 17. Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb: A case report.
    Xiang S; Zeng L; Xiang M; Zhang Y
    Heliyon; 2023 Nov; 9(11):e22515. PubMed ID: 38074875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world experience with capmatinib in
    Illini O; Fabikan H; Swalduz A; Vikström A; Krenbek D; Schumacher M; Dudnik E; Studnicka M; Öhman R; Wurm R; Wannesson L; Peled N; Kian W; Bar J; Daher S; Addeo A; Rotem O; Pall G; Zer A; Saad A; Cufer T; Sorotsky HG; Hashemi SMS; Mohorcic K; Stoff R; Rovitsky Y; Keren-Rosenberg S; Winder T; Weinlinger C; Valipour A; Hochmair MJ
    Ther Adv Med Oncol; 2022; 14():17588359221103206. PubMed ID: 35720834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capmatinib for non-small cell lung cancer.
    Alzofon N; Jimeno A
    Drugs Today (Barc); 2021 Jan; 57(1):17-25. PubMed ID: 33594387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
    Baltschukat S; Engstler BS; Huang A; Hao HX; Tam A; Wang HQ; Liang J; DiMare MT; Bhang HC; Wang Y; Furet P; Sellers WR; Hofmann F; Schoepfer J; Tiedt R
    Clin Cancer Res; 2019 May; 25(10):3164-3175. PubMed ID: 30674502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.